Abiopharma

🔍 Kaye Edward M. MD (Executive)

Company: Stoke Therapeutics, Inc. (STOK)

Report Date: 2025-09-04

Detailed Transactions and Holdings:

• Sold 178,500 shares of Employee Stock Option (Right to Buy) at $8.33 per share (Derivative)
  Date: 2025-09-04 | Code: D | Expires: 2035-03-19 | equity_swap_involved: 0 | shares_owned_after: 37,500.00 | transaction_form_type: 5 | Footnotes: F1, F1, F2
• Sold 144,000 shares of Restricted Stock Units (Derivative)
  Date: 2025-09-04 | Code: D | Expires: 2029-03-20 | equity_swap_involved: 0 | transaction_form_type: 5 | Footnotes: F3, F4, F4, F5

Footnotes:

• F1: The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The equity award was partially canceled for no consideration by mutual agreement of the reporting person and the Issuer.
• F2: The option began vesting on April 15, 2025. Pursuant to the terms of the initial grant, the original number of shares subject to the option vests in ratable increments monthly and the option shall be fully vested on December 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.
• F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
• F4: The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The entire equity award was canceled for no consideration by mutual agreement of the reporting person and the Issuer.
• F5: Pursuant to the terms under which it was granted, the award was scheduled to vest as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.